Takahiro Fujimoto

Takahiro Fujimoto

Auto-generated profile, based on publicly available information

Takahiro Fujimoto

Department of Cell Biology, Faculty of Medicine, Fukuoka University, Fukuoka, 814-0180, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2012 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
TTToshiyuki Tsunoda
Toshiyuki Tsunoda
TOTakeharu Ota
Takeharu Ota
TFTakahiro Fujimoto
Takahiro Fujimoto
KDKeiko Doi
Keiko Doi
YTYoko Tanaka
Yoko Tanaka
SSSenji Shirasawa
Senji Shirasawa
Background: We previously established a three-dimensional (3-D) colonic crypt model using HKe3 cells which are human colorectal cancer (CRC) HCT116 cells with a disruption in oncogenic KRAS, and revealed the crucial roles of oncogenic KRAS both in inhibition of apoptosis and in disruption of cell polarity; however, the molecular mechanism of KRAS-induced these 3-D specific biological changes remains to be elucidated. Results: Among the genes that were upregulated by oncogenic KRAS in this model, we focused on the phosphodiesterase 4B (PDE4B) of which expression levels were found to be higher in clinical tumor samples from CRC patients in comparison to those from healthy control in the public datasets of gene expression analysis. PDE4B2 was specifically overexpressed among other PDE4 isoforms, and re-expression of oncogenic KRAS in HKe3 cells resulted in PDE4B overexpression. Furthermore, the inhibition of PDE4 catalytic activity using rolipram reverted the disorganization of HCT116 cells into the normal physiologic state of the epithelial cell polarity by inducing the apical assembly of ZO-1 (a tight junction marker) and E-cadherin (an adherens junction marker) and by increasing the activity of caspase-3 (an apoptosis marker) in luminal cavities. Notably, rolipram reduced the AKT phosphorylation, which is known to be associated with the disruption of luminal cavity formation and CRC development. Similar results were also obtained using PDE4B2-shRNAs. In addition, increased expression of PDE4B mRNA was found to be correlated with relapsed CRC in a public datasets of gene expression analysis. Conclusions: These results collectively suggested that PDE4B is upregulated by oncogenic KRAS, and also that the inhibition of PDE4 catalytic activity can induce both epithelial cell polarity and luminal apoptosis in CRC, thus highlighting the utility of our 3-D culture (3 DC) model for the KRAS-induced development of CRC in 3-D microenvironment. Indeed, using this model, we found that PDE4B is a promising candidate for a therapeutic target as well as prognostic molecular marker in CRC. Further elucidation of the signaling network of PDE4B2 in 3 DC would provide a better understanding of CRC in vivo.

25 July 2011 in BMC Neurology
Verified
Journal Article
Open access
PDF file
FGFukuoka Kinki Parkinson's Disease Study Group
Fukuoka Kinki Parkinson's Disease Study Group
CKChikako Kiyohara
Chikako Kiyohara
Yoshihiro MiyakeYoshihiro Miyake
Yoshihiro Miyake
MKMidori Koyanagi
Midori Koyanagi
TFTakahiro Fujimoto
Takahiro Fujimoto
MNMasaki Nagai
Masaki Nagai
Parkinson's disease (PD) is characterized by alterations in dopaminergic neurotransmission. Genetic polymorphisms involved in dopaminergic neurotransmission may influence susceptibility to PD. We investigated the relationship of catechol-O-methyltransferase (COMT), monoamine oxidase B (MAOB), dopamine receptor (DR) D2 and DRD4 polymorphisms and PD risk with special attention to the interaction with cigarette smoking among 238 patients with PD and 369 controls in a Japanese population. Subjects with the AA genotype of MAOB rs1799836 showed a significantly increased risk of PD (odds ratio (OR) = 1.70, 95% confidence interval (CI) = 1.12 - 2.58) compared with the AG and GG genotypes combined. The AA genotype of COMT rs4680 was marginally associated with an increased risk of PD (OR = 1.86, 95% CI = 0.98 - 3.50) compared with the GG genotype. The DRD2 rs1800497 and DRD4 rs1800955 polymorphisms showed no association with PD. A COMT -smoking interaction was suggested, with the combined GA and AA genotypes of rs4680 and non-smoking conferring significantly higher risk (OR = 3.97, 95% CI = 2.13 - 7.41) than the AA genotype and a history of smoking (P for interaction = 0.061). No interactions of smoking with other polymorphisms were observed. The COMT rs4680 and MAOB rs1799836 polymorphisms may increase susceptibility to PD risk among Japanese. Future studies involving larger control and case populations and better pesticide exposure histories will undoubtedly lead to a more thorough understanding of the role of the polymorphisms involved in the dopamine pathway in PD.

1 June 2012
Verified
Journal Article
Closed access
TOTakeharu Ota
Takeharu Ota
KDKeiko Doi
Keiko Doi
TFTakahiro Fujimoto
Takahiro Fujimoto
YTYoko Tanaka
Yoko Tanaka
MOMasahiro Ogawa
Masahiro Ogawa
TTToshiyuki Tsunoda
Toshiyuki Tsunoda

1 July 2011
Verified
Journal Article
Closed access
YYYasuhiro Yoshida
Yasuhiro Yoshida
TTToshiyuki Tsunoda
Toshiyuki Tsunoda
KDKeiko Doi
Keiko Doi
YTYoko Tanaka
Yoko Tanaka
TFTakahiro Fujimoto
Takahiro Fujimoto
SSSenji Shirasawa
Senji Shirasawa

1 July 2011
Verified
Journal Article
Closed access
TTToshiyuki Tsunoda
Toshiyuki Tsunoda
YTYasuo Takashima
Yasuo Takashima
YYYasuhiro Yoshida
Yasuhiro Yoshida
KDKeiko Doi
Keiko Doi
YTYoko Tanaka
Yoko Tanaka
SSSenji Shirasawa
Senji Shirasawa

1 June 2012
Verified
Journal Article
Closed access
YYYasuhiro Yoshida
Yasuhiro Yoshida
TTToshiyuki Tsunoda
Toshiyuki Tsunoda
KDKeiko Doi
Keiko Doi
TFTakahiro Fujimoto
Takahiro Fujimoto
YTYoko Tanaka
Yoko Tanaka
SSSenji Shirasawa
Senji Shirasawa